Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

NCT07187869 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT07187869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07187869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
February 12, 2026
Completion date
April 7, 2029
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma